Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report

Igawa, Satoshi; Yanagisawa, Nobuyuki; Niwa, Hideyuki; Ishihara, Mikiko; Hiyoshi, Yasuhiro; Otani, Sakiko; Katono, Ken; Sasaki, Jiichiro; Satoh, Yukitoshi; Masuda, Noriyuki

doi:10.3892/ol.2015.3812

Cited by 12 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been also proved to be effective in lung neuroendocrine carcinoma. [ 21 – 23 ] After progression in the liver, the patient was given nab-paclitaxel plus erlotinib which eased the patient's symptom and led to partial remission. This regimen also demonstrated significant activity during the second progression and prolonged his survival.…”

Section: Discussionmentioning

confidence: 99%

Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma

Liang

Tong²,

Gu³

et al. 2017

Medicine

View full text Add to dashboard Cite

Rationale:Lung cancer is the leading cause of cancer-related death in the world. Tyrosine kinase inhibitors (TKIs), which target mutated epidermal growth factor receptor (EGFR), have been the first-line treatment of late-stage lung adenocarcinoma harboring EGFR mutation. EGFR mutations are mostly identified in lung adenocarcinoma. However, it is rarely seen in lung neuroendocrine carcinoma, and treatment strategies remain under reported.Patient concerns:Here, we describe a 54-year-old Chinese man diagnosed with lung adenocarcinoma (cT4N3M1b, stage IV) with neuroendocrine differentiation and L858R mutation on exon 21. He developed progressive disease in liver 4 months later, and the biopsy of liver metastases showed neuroendocrine carcinoma maintained the same EGFR mutation.Diagnoses:Lung adenocarcinoma and neuroendocrine carcinoma were identified by biopsy.Interventions:After a combined treatment with nab-paclitaxel and erlotinib, the patient achieved partial remission.Outcomes:The patient's overall survival was 27 months.Lessons:This case highlights that EGFR mutated lung neuroendocrine carcinoma is not responsive to single-agent EGFR-TKI. However, combined application with nab-paclitaxel can improve its efficacy and prolong the patient's survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Marked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma

Liang

Tong²,

Gu³

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…In addition, both our patients had an ECOG PS of 2 at the initiation of combination chemotherapy; therefore, this combination therapy and maintenance therapy with nab −paclitaxel is feasible for patients with a poor PS and advanced thymic carcinoma. Furthermore, this is the first report to demonstrate that combination chemotherapy comprising carboplatin plus nab −paclitaxel and maintenance therapy with nab −paclitaxel is effective for undifferentiated thymic carcinoma, a rare type of thymic carcinoma, although previous reports had showed the efficacy of this treatment in other subtypes of thymic carcinoma [ 10 , 11 , 12 , 13 ]. Several retrospective [ 3 , 4 ] and prospective [ 5 , 6 , 7 ] studies have reported that carboplatin plus solvent-based paclitaxel is an effective treatment for thymic cancer.…”

Section: Discussionmentioning

confidence: 95%

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports

et al. 2020

View full text Add to dashboard Cite

A standard chemotherapy regimen for advanced thymic carcinoma has not yet been established. We treated 2 cases of thymic carcinoma with carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel, and nab-paclitaxel maintenance therapy. The first case was a 68-year-old female, admitted for dyspnea and left shoulder pain. Chest computed tomography (CT) showed a huge mass in the anterior mediastinum, pleural and pericardial effusions, and multiple lung metastases. Specimens obtained from the anterior mediastinal mass by CT-guided needle biopsy revealed squamous cell carcinoma of the thymus, which was in stage IVB. The patient was administered carboplatin plus nab-paclitaxel as first-line treatment. After 3 cycles of chemotherapy, a partial response was observed with marked shrinkage of the tumor. Following 6 cycles of chemotherapy, nab-paclitaxel maintenance therapy was initiated. Disease progression was seen 9.1 months after initiation of treatment. The patient experienced no serious adverse events. The second case was a 70-year-old male who had productive cough, dyspnea, and right-sided chest pain. Chest CT revealed a huge mass in the anterior mediastinum, pericardial effusion, and multiple lymphadenopathies. Specimens obtained from station 11s by endobronchial ultrasound-guided transbronchial needle aspiration revealed undifferentiated thymic carcinoma, which was in stage IVB. Six cycles of carboplatin plus nab-paclitaxel were administered, followed by 5 cycles of nab-paclitaxel for maintenance. A partial response was seen, which was sustained for more than 13 months. The patient experienced no serious adverse events. These cases show that chemotherapy with carboplatin plus nab-paclitaxel and nab-paclitaxel as maintenance therapy can be a useful regimen for advanced thymic carcinoma.

show abstract

“…To date, 19 cases of resection for thymic LCNEC have been reported in the English language literature [[6], [7], [8], [9], [10], [11], [12], [13], [14], [15]]. The author summarized a total of 20 patients, including the present case, with ages between 42 and 90 (mean age, 57) years (Table 1).…”

Section: Discussionmentioning

confidence: 98%